NAFDAC Pharmaceutical Import Nigeria: A 2026 Guide for UK Exporters

Nigeria is the largest pharmaceutical market in West Africa and one of the most significant destinations for imported finished medicines on the continent. Its population, the rapid expansion of tertiary care, and a persistent reliance on imports for specialty, oncology and shortage lines make it a priority market for UK exporters of UK-licensed medicines. For hospital procurement teams, Ministry of Health buyers and licensed distributors inside Nigeria, the central question is always the same: how does a UK-authorised medicine move compliantly through NAFDAC and into clinical use?

This guide is written for the Nigerian buyer and the UK supply chain that serves it. It sets out the role of NAFDAC, the general registration and import permit pathway, the documents typically required, how UK-licensed supply maps onto NAFDAC expectations, the buyer's in-country routes for medicines that are not yet routinely registered, cold chain considerations, and the pitfalls that most often delay a consignment. It speaks in correct but general terms where specific fees, article numbers and exact timelines vary or are revised, and points to the official NAFDAC guidelines for the current detail.

Who Is NAFDAC and What Does It Regulate?

The National Agency for Food and Drug Administration and Control (NAFDAC) is the Nigerian federal regulator responsible for the quality, safety and registration of food, drugs, medical devices, cosmetics, chemicals and packaged water. For pharmaceuticals, NAFDAC is the gatekeeper: it registers medicines, assesses manufacturing quality, tests product samples, inspects facilities and controls importation through its port operations.

The governing principle is straightforward and strict. Under the NAFDAC Act, no drug may be manufactured, imported, advertised, sold, distributed or used in Nigeria unless it has been registered with NAFDAC. In practice this means that routine commercial supply of any medicine, including a UK-licensed product, depends on that product holding a valid NAFDAC certificate of registration, held by a Nigerian-incorporated local representative. Separate, controlled mechanisms exist for samples needed during registration and for defined patient or institutional situations, but the default rule is registration first.

Several arms of the agency matter to a UK supply chain. The Registration and Regulatory Affairs directorate handles dossier assessment and product registration. The laboratory services arm performs sample testing. The Port Inspectorate Directorate controls clearance of consignments at the point of entry. Understanding which arm owns which step helps a buyer plan realistically rather than treating NAFDAC as a single undifferentiated checkpoint.

The General Registration and Import Pathway

For a foreign-manufactured, UK-licensed medicine intended for routine supply, the journey through NAFDAC follows a recognisable sequence. The exact steps and their order can be refined by current guidelines, but the structure is stable.

1. Appoint a Nigerian local representative

A foreign manufacturer or marketing authorisation holder cannot register a product in its own name in Nigeria. NAFDAC issues the certificate of registration to a Nigerian-incorporated entity, the local representative, appointed through a notarised power of attorney that confirms brand ownership and authority to act. This local representative holds the registration, manages renewals and variations, applies for permits, and is the agency's point of contact. Selecting the right representative, with genuine hospital and distribution reach, is one of the most consequential decisions a UK exporter and its Nigerian partner make.

2. Apply for a permit to import registration samples

Before laboratory assessment can begin, NAFDAC issues a written permit allowing the importer to bring in product samples for testing. Samples are imported against this permit, not as ordinary commercial stock.

3. Submit the registration dossier and samples for assessment

The local representative submits the application, the dossier and the documentation pack to NAFDAC. Product samples undergo laboratory testing to verify identity and quality against the declared specifications, and the manufacturing site is assessed for Good Manufacturing Practice compliance, which can include facility inspection.

4. Receive the certificate of registration

On successful assessment, NAFDAC issues a certificate of registration and a NAFDAC registration number for the product. The certificate is generally valid for five years and is renewable, so the heaviest investment is front-loaded into the first registration cycle.

5. Import and clear commercial consignments

With the product registered, commercial consignments are imported and presented for clearance to the Port Inspectorate Directorate at the point of entry. Clearance is supported by shipping documentation, the relevant NAFDAC and Pharmacists Council of Nigeria permits, and payment of inspection and analysis fees, followed by physical inspection before release to the importer's warehouse.

Documents Typically Required

NAFDAC's documentation requirements for imported drug products are detailed and are revised from time to time, so the local representative should always work from the current NAFDAC guidelines. For a UK-licensed product, the package generally combines Nigerian corporate and legal documents with the UK-origin quality evidence that a UK exporter is well placed to supply.

Two documents deserve particular attention from the UK side. The first is the Certificate of Pharmaceutical Product. NAFDAC expects a CPP in WHO format, and for a UK-licensed medicine this is issued by the MHRA Export Certificate service. It confirms that the product is the same UK-authorised medicine, made at an inspected site, and it sits at the heart of the dossier. MHRA CPP issuance takes time, so the request should be raised well ahead of any filing deadline.

The second is batch-level evidence. Each consignment should travel with a certificate of analysis for the batch and Qualified Person batch release documentation. Where the UK exporter is not the manufacturer, it coordinates with the manufacturer's Qualified Person to obtain release documentation in advance of despatch. We cover the full UK-side export pack in our UK pharmaceutical import documentation guide.

How UK-Licensed Supply Fits NAFDAC Expectations

UK-licensed, MHRA-authorised finished medicines are a strong match for NAFDAC's framework, and that is the core of the value a UK exporter brings. NAFDAC's assessment is built around confidence in the country-of-origin licence and the manufacturing quality behind it. A medicine that is licensed by the MHRA, made at an MHRA-inspected site, and supplied with a WHO-format CPP, a GMP certificate, marketing authorisation evidence and full batch documentation, arrives carrying exactly the assurances NAFDAC is looking for.

It is important to be precise about what is being supplied. Euro Biom supplies UK-licensed finished medicines only. We do not supply unlicensed medicines, specials, vaccines, biologics, biosimilars, insulin, blood products or controlled drugs. For a Nigerian buyer, the practical benefit of working with a UK exporter focused on licensed product is traceability: every consignment can be evidenced back to a UK marketing authorisation and an inspected manufacturing site, which simplifies both the NAFDAC dossier and the buyer's own internal governance.

For a market-level view of how Euro Biom supports Nigerian buyers, see our UK pharmaceutical supplier to Nigeria page, and for a side-by-side view of how NAFDAC compares with other regulators across our markets, the regulator comparison tool is a useful reference.

The Named Patient and Special Import Route: A Buyer's In-Country Mechanism

Not every medicine a Nigerian hospital needs is routinely registered with NAFDAC. For specialty, oncology, rare disease and shortage situations, a patient may need a specific UK-licensed product before it carries a full Nigerian registration. Nigeria, like most regulated markets, operates controlled mechanisms that allow defined medicines to be imported outside routine commercial registration, including permits for registration samples and arrangements for specific clinical or emergency needs.

The essential point to understand is whose mechanism this is. The named patient or special import route is the Nigerian buyer's in-country regulatory pathway, not something a UK exporter grants or controls. The hospital pharmacy, the institution or the licensed importer applies to NAFDAC for the appropriate authorisation for a specific UK-licensed product and a specific need. The UK exporter's role is to supply that UK-licensed, MHRA-authorised product against the buyer's authorisation, with complete certificate-of-origin and batch documentation so the consignment can be cleared and traced.

Framed correctly, this is simply the import route by which a UK-licensed medicine reaches an individual Nigerian patient. The product is licensed in the UK throughout; what the named patient mechanism provides is the destination-country permission to import it for that defined use ahead of routine registration. Our named patient supply page explains the UK-side process that sits behind this, including the documentation a Nigerian buyer can expect to receive.

Cold Chain and GDP Considerations

A meaningful share of UK pharmaceutical exports to Nigeria involves temperature-sensitive product. Where a UK-licensed medicine requires controlled storage, the cold chain must be intact and evidenced from the UK warehouse all the way to the Nigerian consignee, and the supporting records form part of what is presented at clearance.

• Validated temperature-controlled storage at the UK exporter, at the manufacturer-specified condition, typically 2 to 8 degrees Celsius for refrigerated lines.
• Qualified shipping containers validated for the ambient profile of the Heathrow to Lagos or Abuja route, including high destination ground temperatures.
• Continuous temperature monitoring via a calibrated data logger accompanying the consignment from packing to acceptance, with any excursion reviewed under an agreed deviation procedure.
• A Good Distribution Practice statement from the UK exporter covering the full chain from UK warehouse, through Heathrow cargo handling, to the Nigerian point of entry and onward delivery.

Heathrow runs direct services to Lagos with a flight time of around six and a half hours, and Abuja is well connected via direct and one-stop routings, so same-day or next-day despatch from a Heathrow-proximate warehouse is achievable for urgent consignments. For the practical mechanics, see our UK cold chain pharmaceutical supply page.

Common Pitfalls and How to Avoid Them

Most Nigeria-bound supply problems trace back to a small set of avoidable errors. Each is straightforward to design out at the planning stage.

• Starting too late. Registration and the local representative appointment are long-lead items. Treating them as paperwork to be done in parallel with first orders is the most common cause of missed timelines.
• Wrong-format or out-of-date CPP. NAFDAC expects a current WHO-format CPP from the MHRA. Internal export certificates that are not in WHO format, or a CPP that has aged out, cause rejections. Build the MHRA request in early.
• Weak local representative selection. The representative holds the registration and is the NAFDAC interface. Choosing on the basis of the lowest retainer rather than genuine capability and hospital reach undermines the whole project.
• Importing ahead of registration. Other than the controlled sample and specific-need permits, commercial stock cannot be imported before the product is registered. Attempting to do so risks the consignment.
• Incomplete batch documentation. A missing certificate of analysis or batch release record at clearance stalls the consignment at port. Standardise the export pack so every shipment is complete.
• Cold chain without a deviation plan. An excursion with no pre-agreed handling procedure can leave a consignment in limbo. Agree the deviation procedure in the supply contract before the first shipment.

How Euro Biom Supports Supply into Nigeria

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines and operate the UK leg of the supply chain for Nigerian hospitals, Ministry of Health buyers, NGOs and licensed distributors. We are not a manufacturer, a regulatory consultancy or a Nigerian local representative; we work alongside the buyer's local representative, who manages the NAFDAC interface.

Across a Nigeria supply project, our role typically covers:

• UK-side documentation. Coordinating the MHRA Certificate of Pharmaceutical Product with the manufacturer or MA holder, retrieving GMP and marketing authorisation evidence, and assembling the GDP-compliant export pack with certificate of analysis, batch release, packing list, commercial invoice and certificate of origin, with legalisation where the importer requires it.
• Cold chain logistics from Heathrow. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers and Heathrow despatch with direct routing to Lagos and Abuja.
• Named patient and special import support. Supplying UK-licensed product against the authorisation that the Nigerian hospital or importer obtains from NAFDAC, with full origin and batch documentation.
• Shortage supply. Rapid response where a UK-licensed line is needed at short notice, drawing on Heathrow proximity and MHRA-licensed inventory.

For more on the broader service, see our services overview, the Nigeria supplier page, and the import documentation guide. To discuss a specific Nigeria-bound requirement, please contact our team.